Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

LYPLA2 inhibition alleviates hepatic sinusoidal obstruction syndrome by suppressing pSTAT3-dependent HSP60 transcription.

Created on 15 Nov 2026

Authors

Xiaofei Ren, Haiwang Zhang, Rutao Hong, Xinyan Du

Published in

Biochimica et biophysica acta. Molecular basis of disease. Volume 1873. Issue 3. Pages 168525. Nov 14, 2026. Epub Nov 14, 2026.

Abstract

To investigate the underlying molecular mechanisms involved in the progression of hepatic sinusoidal obstruction syndrome (HSOS) and the mechanisms by which low-molecular-weight heparin (LMWH) alleviates HSOS. Monocrotaline (MCT) was administered to establish rat and cellular models of HSOS. Rats received subcutaneous injections of enoxaparin (EPN; 8 mg/kg) at three time points: 48 h, 24 h, and 30 min prior to MCT administration. Liver tissue protein expression profiles from the Control, MCT, and MCT + EPN groups were subsequently analyzed using proteomics. Lysophospholipase 2 (LYPLA2) inhibitor ML349 (35 mg/kg) was intraperitoneally injected daily for 7 consecutive days before MCT administration. The results showed that LYPLA2 protein level in liver tissues of HSOS rats was increased (log2FC = 1.05, p = 0.047) but decreased by EPN (log2FC = -1.11, p = 0.037). Treatment with LYPLA2 inhibitor ML349 or LYPLA2 knockdown alleviated MCT-induced liver tissues and human hepatic sinus endothelial cells (HSECs) injury by reducing cell apoptosis and inflammation. The underlying mechanism was that LYPLA2 inhibition decreased pSTAT3 level in cytoplasm and nucleus. Meanwhile, LYPLA2 inhibition increased palmitoylation of pSTAT3, which is known to mediate plasma membrane retention of pSTAT3. The decrease of pSTAT3 in nucleus suppressed the transcription of heat shock protein 60 (HSP60). HSP60, a driver of HSOS progression, overexpression reversed the effects caused by ML349 or LYPLA2 knockdown. The observations demonstrate that LYPLA2 inhibition alleviates MCT-induced liver injury by inhibiting pSTAT3-mediated HSP60 transcription, suggesting that ML349 may confer preventive protection against HSOS.

PMID:
43033751
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement